FDA Calls for Opana ER ' s Removal Due to Abuse Concerns

On June 8, the FDA asked Endo Pharmaceuticals to pull its opioid pain medication, reformulated Opana ER, from the U.S. market because of concerns about abuse.
Source: AAFP News - Category: Primary Care Source Type: news